Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pubertal development in 46,XY patients with NR5A1 mutations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. CPMS-improving patient care in Europe via virtual case discussions

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. ENDO-ERN expert opinion on the differential diagnosis of pubertal delay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Thyroid Disease and Hepatocellular Carcinoma Survival: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: Replicating the physiological cortisol secretion is key in the treatment of glucocorticoid insufficient individuals and optimization may enhance quality of life. The study investigates fatigue measured by ecological momentary assessments in patients treated with conventional hydrocortisone compared with once-daily dual-release hydrocortisone (Plenadren).

METHODS: A 21-week open-label switch pilot trial included 30 patients with adrenal insufficiency due to hypopituitarism. Fatigue was assessed four times daily for 20 days using a momentary item version of the Multidimensional Fatigue Inventory on patients' usual hydrocortisone regimen. Participants switched treatment to an identical daily dose of Plenadren for 16 weeks where fatigue assessments were repeated. Change in fatigue and diurnal variation of fatigue was analyzed using mixed models for repeated measurements.

RESULTS: In four out of five fatigue subscales fatigue was significantly reduced 0.7-1.1 points (scales ranging from 4 to 20), when treated with Plenadren compared with conventional hydrocortisone, corresponding to small effect sizes below the scale-specific minimal important changes. However, 33% of the participants completing the study (9/27) experienced reductions in fatigue above the minimal important change. On Plenadren, we found larger between-person variances and smaller within-person variances. Finally, we identified diurnal fatigue curves for both treatments.

CONCLUSIONS: The Plenadren-related reduction in fatigue was significant but not necessarily of clinical importance when looking at a group level. However, there was a large interindividual variation in treatment effect, why patients with a large benefit in quality of life should be identified. Future RCTs should be powered to detect the effect magnitudes identified here.

OriginalsprogEngelsk
TidsskriftEndocrine
Vol/bind71
Udgave nummer2
Sider (fra-til)467-475
Antal sider9
ISSN1355-008X
DOI
StatusUdgivet - feb. 2021

ID: 61433137